Now showing items 1-3 of 3
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)
Antiangiogenic drugs are potentially a useful supplement to neoadjuvant chemotherapy for a subgroup of patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, but reliable biomarkers for ...
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
Background: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...
The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer
(Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2017)
Purpose: Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated ...